Article Type
Article
Changed
Fri, 03/22/2024 - 10:44
Display Headline
Cancer Data Trends 2024: Colorectal Cancer

Click here to view more from Cancer Data Trends 2024.

References

1. May FP, Yano EM, Provenzale D, et al. Barriers to follow-up colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol. 2019;17(3):469-476. doi:10.1016/j.cgh.2018.05.022

2. San Miguel Y, Demb J, Martinez ME, Gupta S, May FP. Time to colonoscopy after abnormal stool-based screening and risk for colorectal cancer incidence and mortality. Gastroenterology. 2021;160(6):1997-2005.e3. doi:10.1053/j.gastro.2021.01.219

3. Coronado GD, Rawlings AM, Petrik AF, et al. Precision patient navigation to improve rates of follow-up colonoscopy, an individual randomized effectiveness trial. Cancer Epidemiol Biomarkers Prev. 2021;30(12):2327-2333. doi:10.1158/1055-9965.EPI-20-1793

4. Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget stool RNA test for colorectal cancer screening. JAMA. 2023;330(18):1760- 1768. doi:10.1001/jama.2023.22231

5. McNamara D. Two multitarget stool tests show promise for CRC screening: studies. Medscape. Published October 22, 2023. Accessed December 20, 2023. https://www.medscape.com/viewarticle/997609#vp_1

6. Clinical validation of an optimized multi-target stool DNA (Mt-sDNA 2.0) test, for colorectal cancer screening “BLUE-C.” ClinicalTrials. gov identifier: NCT04144738. Updated September 1, 2023. Accessed December 20, 2023. https://www.clinicaltrials.gov/study/ NCT04144738

7. Universal Diagnostics. Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity. Press Release. Published May 2023. Accessed January 26. 2024.

Author and Disclosure Information

Reviewed by Divya Bhatt, MD, MS
Assistant Professor, Division of Digestive and Liver Diseases
University of Texas Southwestern
Medical Center
Staff Physician, Department of Internal Medicine
Division of Gastroenterology
VA North Texas Health Care System
Dallas, TX

Divya Bhatt, MD, has disclosed the following relevant financial relationship:
Received research grant from: VA North Texas Health Care System 2019-2021

Publications
Federal Practitioner
Topics
Cancer
Colon and Rectal
Author and Disclosure Information

Reviewed by Divya Bhatt, MD, MS
Assistant Professor, Division of Digestive and Liver Diseases
University of Texas Southwestern
Medical Center
Staff Physician, Department of Internal Medicine
Division of Gastroenterology
VA North Texas Health Care System
Dallas, TX

Divya Bhatt, MD, has disclosed the following relevant financial relationship:
Received research grant from: VA North Texas Health Care System 2019-2021

Author and Disclosure Information

Reviewed by Divya Bhatt, MD, MS
Assistant Professor, Division of Digestive and Liver Diseases
University of Texas Southwestern
Medical Center
Staff Physician, Department of Internal Medicine
Division of Gastroenterology
VA North Texas Health Care System
Dallas, TX

Divya Bhatt, MD, has disclosed the following relevant financial relationship:
Received research grant from: VA North Texas Health Care System 2019-2021

Click here to view more from Cancer Data Trends 2024.

Click here to view more from Cancer Data Trends 2024.

References

1. May FP, Yano EM, Provenzale D, et al. Barriers to follow-up colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol. 2019;17(3):469-476. doi:10.1016/j.cgh.2018.05.022

2. San Miguel Y, Demb J, Martinez ME, Gupta S, May FP. Time to colonoscopy after abnormal stool-based screening and risk for colorectal cancer incidence and mortality. Gastroenterology. 2021;160(6):1997-2005.e3. doi:10.1053/j.gastro.2021.01.219

3. Coronado GD, Rawlings AM, Petrik AF, et al. Precision patient navigation to improve rates of follow-up colonoscopy, an individual randomized effectiveness trial. Cancer Epidemiol Biomarkers Prev. 2021;30(12):2327-2333. doi:10.1158/1055-9965.EPI-20-1793

4. Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget stool RNA test for colorectal cancer screening. JAMA. 2023;330(18):1760- 1768. doi:10.1001/jama.2023.22231

5. McNamara D. Two multitarget stool tests show promise for CRC screening: studies. Medscape. Published October 22, 2023. Accessed December 20, 2023. https://www.medscape.com/viewarticle/997609#vp_1

6. Clinical validation of an optimized multi-target stool DNA (Mt-sDNA 2.0) test, for colorectal cancer screening “BLUE-C.” ClinicalTrials. gov identifier: NCT04144738. Updated September 1, 2023. Accessed December 20, 2023. https://www.clinicaltrials.gov/study/ NCT04144738

7. Universal Diagnostics. Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity. Press Release. Published May 2023. Accessed January 26. 2024.

References

1. May FP, Yano EM, Provenzale D, et al. Barriers to follow-up colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol. 2019;17(3):469-476. doi:10.1016/j.cgh.2018.05.022

2. San Miguel Y, Demb J, Martinez ME, Gupta S, May FP. Time to colonoscopy after abnormal stool-based screening and risk for colorectal cancer incidence and mortality. Gastroenterology. 2021;160(6):1997-2005.e3. doi:10.1053/j.gastro.2021.01.219

3. Coronado GD, Rawlings AM, Petrik AF, et al. Precision patient navigation to improve rates of follow-up colonoscopy, an individual randomized effectiveness trial. Cancer Epidemiol Biomarkers Prev. 2021;30(12):2327-2333. doi:10.1158/1055-9965.EPI-20-1793

4. Barnell EK, Wurtzler EM, La Rocca J, et al. Multitarget stool RNA test for colorectal cancer screening. JAMA. 2023;330(18):1760- 1768. doi:10.1001/jama.2023.22231

5. McNamara D. Two multitarget stool tests show promise for CRC screening: studies. Medscape. Published October 22, 2023. Accessed December 20, 2023. https://www.medscape.com/viewarticle/997609#vp_1

6. Clinical validation of an optimized multi-target stool DNA (Mt-sDNA 2.0) test, for colorectal cancer screening “BLUE-C.” ClinicalTrials. gov identifier: NCT04144738. Updated September 1, 2023. Accessed December 20, 2023. https://www.clinicaltrials.gov/study/ NCT04144738

7. Universal Diagnostics. Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity. Press Release. Published May 2023. Accessed January 26. 2024.

Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Cancer
Colon and Rectal
Article Type
Article
Display Headline
Cancer Data Trends 2024: Colorectal Cancer
Display Headline
Cancer Data Trends 2024: Colorectal Cancer
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Slideshow
Un-Gate On Date
Thu, 03/07/2024 - 18:45
Use ProPublica
CFC Schedule Remove Status
Thu, 03/07/2024 - 18:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Slide
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media
Caption
<p>Colorectal cancer (CRC) is frequently diagnosed in patients who have a positive fecal&nbsp; immunochemical test (FIT), leading to a significant concern regarding missed colonoscopies.&nbsp;</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>&nbsp;</p><p>Although factors like scheduling conflicts and a lack of transportation prevent&nbsp;some veterans&nbsp;from undergoing colonoscopies, a recent analysis showed the most common reason is that patients simply chose not to follow up. Interventions are needed to reverse patient hesitancy to increase colonoscopy completion following a positive FIT.</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>Delay in undergoing a colonoscopy after a positive FIT is associated with a higher risk of CRC death and late-stage CRC. Interventions to improve CRC outcomes should prioritize scheduling a colonoscopy within 1 year of an abnormal FIT result.</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>Patient navigators improved completion rates of colonoscopy after a positive FIT, while also reducing the time to schedule the procedure and the number of missed appointments. This intervention presents the potential to help mitigate delayed or missed colonoscopies after a positive FIT.</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>Several stool-based tests (multitarget DNA and RNA) are being tested with improved sensitivity and specificity compared to current screening methods. Liquid biopsy, or blood-based testing, is also under development. These less invasive screening methods should increase access to CRC screening.</p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p><sup>mt-sDNA, multitarget stool DNA; mt-sRNA, multitarget stool RNA</sup></p>
Disable zoom
Off
Media Folder
Media Root
Caption
<p>The SIGNAL-C blood screening test uses a&nbsp;combination of circulating tumor DNA (ctDNA) methylation and fragmentation with single targeted sequencing analysis and advanced computational biology and machine learning algorithms.</p>
Disable zoom
Off
Media Folder
Media Root